The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.

Alessandro Armuzzi, Luisa Guidi, Gionata Fiorino, Natalia Manetti, Ambrogio Orlando, Angela Variola, Stefanos Bonovas, Fabrizio Bossa, Giovanni Maconi, Renata D'Incà, Paolo Lionetti, Laura Cantoro, Walter Fries, Maria L. Annunziata, Francesco Costa, Maria M. Terpin, Livia Biancone, Claudio C. Cortelezzi, Arnaldo Amato, Sandro ArdizzoneSilvio Danese, Giulia Rizzuto, Arianna Massella, Angelo Andriulli, Alessandro Massari, Greta Lorenzon, Silvia Ghione, Anna Kohn, Agostino Ventra, Vito Annese, Mariabeatrice Principi, Maria Di Girolamo, Angela Bertani, Silvia Saettone, Roberto Tari, Carlo Petruzzellis, Francesco W. Guglielmi, Silvia Mazzuoli, Maria Cappello, Anna Viola, Fabiana Castiglione, Olga Nardone, Antonio Di Sabatino, Simone Saibeni, Cristina Bezzio, Luigi Caserta, Maria Caterina Parodi, Gianmichele Meucci, Agostino Colli, Anna Ronchetti, Maurizio Vecchi, Lorenzo Bertani, Matteo A. Bosani, Edoardo Tronconi, Gianni Imperiali, Raffaele Salerno, Francesca Rogai, Stefano Milani, Sara Renna, Andrea Geccherle, Giuseppina Martino, Andrea Cassinotti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

87 Citazioni (Scopus)

Abstract

BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease. METHODS: A prospective, multicenter, cohort study using a structured database. RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab. The mean follow-up was 4.3 ± 2.8 months, and the total follow-up time was 195 patient-years. After 2061 infusions, 66 serious adverse events were reported (12.1%), 38 (6.9%) of them were infusion-related reactions. The biosimilar had to be stopped in 29 (5.3%) cases for severe infusion reactions (8 naive, 19 previous exposed, and 2 switch), and in further 16 patients (2.9%) for other serious adverse events. Infusion reactions were significantly more frequent in patients pre-exposed to infliximab than to other anti-tumor necrosis factor alpha (incidence rate ratio = 2.82, 95% CI: 1.05-7.9). The efficacy of the biosimilar was evaluated in 434 patients who received treatment for at least 8 weeks, using time-to-event methods for censored observations: 35 patients were primary failures (8.1%). After further 8, 16, and 24 weeks, the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive, 97.2%, 85.2%, and 62.2% for pre-exposed, and 94.5%, 90.8%, and 78.9% for switch, respectively (log-rank P = 0.64). CONCLUSIONS: Although no direct comparison was performed, preliminary data on efficacy and safety of CT-P13 were in line with those of infliximab.
Lingua originaleEnglish
pagine (da-a)233-243
Numero di pagine11
RivistaInflammatory Bowel Diseases
Volume2017
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Crohn's disease, ulcerative colitis, inflammatory bowel disease, Infliximab, Remsima, Inflectra, biosimilar, CT-P13

Fingerprint Entra nei temi di ricerca di 'The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.'. Insieme formano una fingerprint unica.

Cita questo